Israeli biotech Silenseed has completed a Phase 1/2a clinical study of its siG12D LODER treatment in 15 patients with Locally Advanced Pancreatic Cancer (LAPC). The treatment combined with chemotherapy was well tolerated and demonstrated promising efficacy with durable responses.

http://silenseed.com/?page_id=2539